Pfiz­er and Alvotech look to in­ter­change­abil­i­ty to stand out in a crowd­ed Hu­mi­ra biosim­i­lar field

With sev­en adal­i­mum­ab biosim­i­lars lined up for a stag­gered launch next year, com­pa­nies are do­ing what they can now to dif­fer­en­ti­ate them­selves from the pack vy­ing for one of the world’s best-sell­ing drugs of all time.

Both Pfiz­er and Te­va-part­nered Alvotech an­nounced sep­a­rate­ly on Fri­day and Mon­day that they are seek­ing to ob­tain an in­ter­change­abil­i­ty des­ig­na­tion for their Hu­mi­ra fol­low-ons. The des­ig­na­tion, if FDA signs off, would mean that phar­ma­cists could au­to­mat­i­cal­ly sub­sti­tute the Hu­mi­ra biosim­i­lars from both com­pa­nies with­out a doc­tor’s in­put.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER